Lv3
370 积分 2024-11-21 加入
Genomic and epigenomic ctDNA profiling in liquid biopsies from heavily pre-treated patients with DNA damage response-deficient tumors
8小时前
求助中
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
23天前
已完结
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
23天前
已完结
Pelvic peritonectomy versus rectosigmoid resection in advanced epithelial ovarian cancer with Douglas pouch involvement: a systematic review and meta-analysis
25天前
已关闭
PARP Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real‐World Study in China
25天前
已完结
Secondary Cytoreductive Surgery for Ovarian Cancer With Second Platinum‐Sensitive Recurrence: A Multicentre Retrospective Cohort Study
25天前
已完结
Combination of PARP Inhibitor and Antiangiogenic Therapy Following Disease Progression in Patients With Epithelial Ovarian Cancer Undergoing PARP Inhibitor Maintenance Therapy: A Real‐World Study
25天前
已完结
Does the primary treatment sequence affect post‐relapse survival in recurrent epithelial ovarian cancer? A real‐world multicentre retrospective study
28天前
已完结
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery
29天前
已完结
Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial
1个月前
已完结
皖公网安备34019202002308
